Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
Year: 2017
Type: article
Abstract: The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was -125.4 mL/year (95% CI -168.1 to -82.7) in the nintedanib group and -189.7 mL/year (95% CI -229.8 to -149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies. These results support a benefit of nintedanib on slowing progression of idiopathic pulmonary fibrosis beyond 52 weeks.
Source: Thorax
Institutions: National Institute for Health and Care Research, NIHR Southampton Respiratory Biomedical Research Unit, University of Southampton, Heidelberg University, German Center for Lung Research, Instituto Nacional de Enfermedades Respiratorias, Hôpital Bichat-Claude-Bernard, LungenClinic Grosshansdorf, Universitair Ziekenhuis Leuven, Peking Union Medical College Hospital, Boehringer Ingelheim (France), Boehringer Ingelheim (Germany), Ruhrlandklinik, University of Duisburg-Essen
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Boehringer Ingelheim
OpenAlex ID: W2763004052
